

## Lesotho

### Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Lesotho						
<b>2. Vaccine grant number:</b>	12-LSO-08a-Y, 1216-LSO-12c-X, 17-LSO-12c-X, 18-LSO-12d-X, 18-LSO-25a-Y, 1922-LSO-12d-X						
<b>3. Date of Decision Letter:</b>	30 September 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	30 November 2012						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Pneumococcal , Routine						
<b>6. Vaccine type:</b>	Pneumococcal						
<b>7. Requested product presentation and formulation of vaccine:</b>	PCV13, 4 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2014-2022						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2014-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	2,118,047	154,500	285,500	279,500	-	-	2,837,547
<b>10. Vaccine introduction grant</b>							
	<b>Approval</b>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2012	12-LSO-08a-Y					100,000
	<b>Disbursement</b>						
	<b>Disbursement date</b>						<b>Amount (US\$)</b>
	01 October, 2014						100,000
<b>11. Product switch grant</b>							
	<b>Approval</b>						
	<i>Approval</i>						
	<b>Year</b>	<b>Grant Number</b>					<b>Amount (US\$)</b>
	2018	18-LSO-25a-Y					25,877
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2014-2019		2020					
	Number of vaccine doses			48,400				
Annual Amounts (US\$)	2,118,047		154,500					
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
<b>14. Self-procurement:</b>	Not applicable							
<b>15. Co-financing obligations:</b>	<p>According to the co-financing policy, the Country falls within the group: Preparatory transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>							
Type of supplies to be purchased with Country funds in each year	<b>2020</b>	<b>2021</b>	<b>2022</b>					
Number of vaccine doses	5,600	13,200	15,200					
Number of AD syringes	5,300	12,300	14,200					
Number of re-constitution syringes	-	-	-					
Number of safety boxes	75	150	175					
Value of vaccine doses (US\$)	16,213	38,142	43,871					
Total co-financing payments (US\$) (including freight)	17,000	39,500	45,500					
<b>16. Operational support for campaigns:</b>	Not applicable							
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> 31 March 2020  15 May 2020 </td> </tr> </tbody> </table>					Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020
	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2020 15 May 2020							

	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<b>18. Financial clarifications:</b>  Not applicable		
<b>19. Other conditions:</b>  Not applicable		

Signed by,  
**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019